GO:0036028 protein C inhibitor-thrombin complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0036028 describes a heterodimeric protein complex composed of protein C inhibitor (SERPINA5) and thrombin (F2).
• Formation of the PCI-thrombin complex inhibits the serine protease activity of thrombin, thereby regulating coagulation and fibrinolysis.
• The complex is relevant to interstitial lung disease, where elevated PCI-thrombin levels have been observed.
• Biomarkers of thrombogenic potential, such as those monitoring factor Xa inhibitors, can reflect changes in PCI-thrombin complex formation.
• Pediatric cardiopulmonary bypass surgery alters coagulation and fibrinolytic profiles, including PCI-thrombin complex dynamics.
• Studying GO:0036028 requires methods such as ELISA, mass spectrometry, and CRISPR-based gene editing to dissect its role in health and disease [1,2,3].
Description
The protein C inhibitor-thrombin complex (GO:0036028) is a heterodimeric assembly of protein C inhibitor (SERPINA5) and thrombin (F2) that forms when SERPINA5 binds to and inhibits thrombin's serine protease activity. This complex is a key regulator of hemostasis, balancing procoagulant and anticoagulant forces in the bloodstream. Researchers study this complex to understand thrombotic disorders, inflammatory lung diseases, and the body's response to extracorporeal circulation [1,2,3]. The QuickGO definition explicitly states that formation of the complex inhibits thrombin, highlighting its role as a molecular brake on coagulation. Because thrombin is central to clot formation and platelet activation, its inhibition by SERPINA5 has broad implications for vascular biology and disease. This article provides a comprehensive, citation-backed overview of GO:0036028, covering its structure, assembly, regulation, disease associations, and the experimental models used to investigate it [1,2,3].
protein C inhibitor-thrombin complex At A Glance
| GO ID | GO:0036028 |
|---|---|
| GO term | protein C inhibitor-thrombin complex |
| Ontology | cellular_component |
| Synonym | PCI-thrombin complex; plasma serine protease inhibitor-thrombin complex; protein C inhibitor-coagulation factor II complex; protein C inhibitor-F2 complex; serpin A5-thrombin complex; SERPINA5-thrombin complex |
| Major function | Inhibition of thrombin serine protease activity |
| Complex members | SERPINA5 (protein C inhibitor) and F2 (thrombin) |
| Stoichiometry | Heterodimer (1:1) |
| Associated process | Regulation of blood coagulation and fibrinolysis |
| Disease relevance | Interstitial lung disease, thrombotic disorders, cardiopulmonary bypass complications |
What Is GO:0036028?
GO:0036028 is a cellular component term describing a heterodimeric protein complex that contains protein C inhibitor (SERPINA5) and thrombin (F2). The formation of this complex inhibits the serine protease activity of thrombin, thereby modulating coagulation and fibrinolysis. In essence, it is a molecular trap that neutralizes thrombin's procoagulant function.
Why Is protein C inhibitor-thrombin complex Important in Cell Biology?
The protein C inhibitor-thrombin complex is important because it directly controls thrombin, a master enzyme in blood clotting and inflammation. Dysregulation of this complex can lead to excessive thrombosis or bleeding, and it has been implicated in interstitial lung disease and in the thrombogenic response to cardiopulmonary bypass [1,3]. Understanding GO:0036028 helps researchers develop targeted therapies for coagulation disorders and biomarkers for monitoring anticoagulant therapies.
• Regulates thrombin activity, a central node in the coagulation cascade.
• Modulates fibrinolysis by inhibiting thrombin-activatable fibrinolysis inhibitor (TAFI) activation.
• Elevated in interstitial lung disease, suggesting a role in pulmonary inflammation and fibrosis.
• Altered during pediatric cardiopulmonary bypass, contributing to postoperative bleeding or thrombosis.
• Serves as a potential biomarker for thrombogenic potential of factor Xa inhibitors.
• Provides a model for studying serpin-protease interactions and complex formation.
• May influence cancer progression through thrombin-mediated signaling.
• Relevant to sepsis and disseminated intravascular coagulation.
• Target for anticoagulant drug development.
• Key to understanding sex-specific differences in coagulation (SERPINA5 is estrogen-regulated).
What Happens During protein C inhibitor-thrombin complex?
Recognition and Binding
In simple terms: SERPINA5 finds and grabs thrombin.
Protein C inhibitor (SERPINA5) circulates in plasma and recognizes thrombin (F2) as a target protease. The interaction is mediated by the reactive center loop of SERPINA5, which mimics a substrate for thrombin. Upon binding, a conformational change occurs that locks the two proteins together.
Complex Formation and Thrombin Inhibition
In simple terms: Once bound, thrombin is permanently switched off.
The binding of SERPINA5 to thrombin leads to the formation of a stable heterodimeric complex. This complex traps thrombin in an inactive state, preventing it from cleaving fibrinogen and activating platelets. The inhibition is irreversible, requiring synthesis of new thrombin for activity.
Clearance and Turnover
In simple terms: The complex is removed from the blood.
The PCI-thrombin complex is cleared from circulation by the liver and reticuloendothelial system. Its half-life is relatively short, and levels can be measured in plasma as an indicator of thrombin generation and inhibition [1,3].
Regulation by Cofactors
In simple terms: Other molecules can speed up or slow down complex formation.
Heparin and other glycosaminoglycans accelerate the formation of the PCI-thrombin complex by providing a template for the interaction. Conversely, certain plasma proteins can compete for thrombin, modulating the rate of inhibition.
Key Genes Involved in GO:0036028 protein C inhibitor-thrombin complex
The following genes and proteins are directly involved in the formation, regulation, or study of the protein C inhibitor-thrombin complex.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SERPINA5 | Encodes protein C inhibitor, the serpin that binds and inhibits thrombin | Central to complex formation; target for knockout and overexpression studies |
| F2 | Encodes thrombin, the serine protease that is inhibited | Key coagulation factor; point mutations can alter active site or binding |
| SERPINC1 | Encodes antithrombin, another thrombin inhibitor | Comparative studies of serpin specificity |
| F10 | Encodes factor Xa, which generates thrombin | Upstream regulator of thrombin availability |
| F5 | Encodes factor V, a cofactor in thrombin generation | Modulates thrombin burst |
| F8 | Encodes factor VIII, a cofactor in coagulation | Influences thrombin generation |
| PROC | Encodes protein C, an anticoagulant | Cross-talk with PCI pathway |
| PROS1 | Encodes protein S, a cofactor for protein C | Regulates thrombin generation |
| PLG | Encodes plasminogen, precursor of plasmin | Links to fibrinolysis |
| FGA | Encodes fibrinogen alpha chain | Substrate of thrombin; readout of thrombin activity |
| FGB | Encodes fibrinogen beta chain | Substrate of thrombin |
| FGG | Encodes fibrinogen gamma chain | Substrate of thrombin |
| SERPINE1 | Encodes plasminogen activator inhibitor-1 | Regulates fibrinolysis; interacts with thrombin |
| CPB2 | Encodes thrombin-activatable fibrinolysis inhibitor (TAFI) | Activated by thrombin; linked to PCI in lung disease |
| IL6 | Encodes interleukin-6, an inflammatory cytokine | Induces SERPINA5 expression in inflammation |
| TNF | Encodes tumor necrosis factor | Modulates coagulation and PCI levels |
| ESR1 | Encodes estrogen receptor alpha | Regulates SERPINA5 expression |
| HNF4A | Encodes hepatocyte nuclear factor 4 alpha | Controls SERPINA5 transcription in liver |
How Is protein C inhibitor-thrombin complex Regulated?
The formation and activity of the protein C inhibitor-thrombin complex are regulated at multiple levels. SERPINA5 expression is induced by estrogen and inflammatory cytokines such as IL-6. Heparin and other glycosaminoglycans accelerate complex formation by bridging SERPINA5 and thrombin. In disease states like interstitial lung disease, the balance between thrombin generation and inhibition is shifted, leading to increased PCI-thrombin complexes. Additionally, genetic polymorphisms in SERPINA5 or F2 can alter the rate of complex formation and thrombin inhibition.
protein C inhibitor-thrombin complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SERPINA5 | Interstitial lung disease; thrombosis | SERPINA5 knockout mice; lung fibrosis models |
| F2 | Thrombophilia; bleeding disorders | F2 point mutation knock-in mice; thrombin generation assays |
| CPB2 | Interstitial lung disease; fibrinolysis | CPB2 knockout mice; TAFI activation assays |
| F10 | Anticoagulant therapy monitoring | FXa inhibitor-treated cell models; biomarker assays |
| IL6 | Inflammation-induced coagulation | IL6 knockout mice; cytokine stimulation of hepatocytes |
Interstitial Lung Disease
In interstitial lung disease, elevated levels of PCI-thrombin complex and thrombin-activatable fibrinolysis inhibitor (TAFI) have been observed, suggesting that dysregulated coagulation and fibrinolysis contribute to pulmonary fibrosis and inflammation. The complex may serve as a biomarker for disease activity and a potential therapeutic target.
Thrombotic Disorders and Anticoagulant Monitoring
The PCI-thrombin complex is a marker of thrombin generation and inhibition. In patients receiving factor Xa inhibitors, changes in PCI-thrombin complex levels can reflect the thrombogenic potential of the drug, aiding in monitoring anticoagulant therapy.
Cardiopulmonary Bypass in Children
Pediatric patients undergoing cardiopulmonary bypass show altered coagulation and fibrinolytic profiles, including changes in PCI-thrombin complex formation. This contributes to postoperative bleeding or thrombotic complications and highlights the need for age-specific anticoagulation strategies.
From protein C inhibitor-thrombin complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SERPINA5 knockout increase thrombin activity? | SERPINA5 knockout cell line (e.g., HepG2) or mouse model |
| How do point mutations in F2 affect PCI binding? | F2 point mutation knock-in cell lines (e.g., HEK293) expressing mutant thrombin |
| Can we visualize PCI-thrombin complex in live cells? | Knock-in of fluorescent tags (e.g., GFP) into SERPINA5 or F2 loci |
| What is the effect of SERPINA5 overexpression on coagulation? | SERPINA5 overexpression stable cell lines; plasma clotting assays |
| Which genes regulate PCI-thrombin complex formation? | CRISPR library screening in hepatocytes followed by thrombin activity readout |
| How does heparin affect complex formation? | In vitro binding assays with purified proteins and heparin variants |
How to Study the protein C inhibitor-thrombin complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ELISA | Concentration of PCI-thrombin complex | Clinical biomarker monitoring |
| Mass spectrometry | Mass and sequence of complex components | Proteomic discovery |
| CRISPR-Cas9 knockout | Loss of gene function | Target validation |
| CRISPR point mutation | Specific amino acid changes | Structure-function studies |
| CRISPR knock-in | Tagged or mutant protein expression | Live-cell imaging |
| Overexpression | Increased protein levels | Gain-of-function studies |
| Surface plasmon resonance | Binding kinetics | Affinity measurements |
| Co-immunoprecipitation | Protein-protein interactions | Complex isolation |
ELISA and Immunoassays
Enzyme-linked immunosorbent assays (ELISAs) using antibodies specific for the PCI-thrombin complex can quantify its levels in plasma or cell culture supernatants. This method is widely used to monitor thrombin generation and inhibition in clinical samples [1,3].
Mass Spectrometry and Proteomics
Mass spectrometry-based proteomics can identify and quantify the PCI-thrombin complex in biological samples, providing information on stoichiometry and post-translational modifications. This approach is useful for discovering novel interacting partners.
CRISPR-Cas9 Gene Editing
CRISPR-Cas9 can be used to generate knockout, point mutation, or knock-in cell models to study the function of SERPINA5 and F2 in complex formation. These models allow precise dissection of molecular mechanisms [1,2].
Surface Plasmon Resonance (SPR)
SPR measures real-time binding kinetics between SERPINA5 and thrombin, providing affinity constants and association/dissociation rates. This method is ideal for studying the effect of mutations on complex formation.
How CRISPR Can Be Used to Study GO:0036028 protein C inhibitor-thrombin complex
Knockout
CRISPR knockout of SERPINA5 or F2 in cell lines such as HepG2 or HEK293 can abolish PCI-thrombin complex formation, allowing researchers to study the consequences on thrombin activity and downstream signaling. Knockout models are essential for target validation.
Point Mutation
Introducing point mutations in the reactive center loop of SERPINA5 or the active site of thrombin via CRISPR can reveal critical residues for complex formation and inhibition. Such models help dissect the molecular basis of serpin-protease specificity.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) or epitope tags into endogenous SERPINA5 or F2 loci enables real-time imaging and pull-down of the PCI-thrombin complex in living cells. This approach preserves native regulation.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of SERPINA5 can increase PCI-thrombin complex levels, providing a gain-of-function model to study its effects on coagulation and fibrinolysis.
How EDITGENE Supports protein C inhibitor-thrombin complex Research
Researchers studying protein C inhibitor-thrombin complex-related genes often need to determine whether a candidate gene is causally involved in complex formation, thrombin inhibition, or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for protein C inhibitor-thrombin complex research.
Frequently Asked Questions About protein C inhibitor-thrombin complex
What is the protein C inhibitor-thrombin complex?
It is a heterodimeric protein complex composed of protein C inhibitor (SERPINA5) and thrombin (F2) that inhibits thrombin's serine protease activity.
What genes are involved in the protein C inhibitor-thrombin complex?
The main genes are SERPINA5 (encoding protein C inhibitor) and F2 (encoding thrombin). Other genes such as SERPINC1, F10, and CPB2 modulate the complex.
What is the function of GO:0036028?
GO:0036028 describes the cellular component that inhibits thrombin, thereby regulating coagulation and fibrinolysis.
How is the protein C inhibitor-thrombin complex formed?
SERPINA5 binds to thrombin via its reactive center loop, forming an irreversible complex that traps thrombin in an inactive state.
What diseases are associated with the protein C inhibitor-thrombin complex?
It is associated with interstitial lung disease, thrombotic disorders, and complications of cardiopulmonary bypass [1,2,3].
How can I study the protein C inhibitor-thrombin complex in the lab?
Common methods include ELISA, mass spectrometry, surface plasmon resonance, and CRISPR-based gene editing [1,2,3].
What are the synonyms for protein C inhibitor-thrombin complex?
Synonyms include PCI-thrombin complex, plasma serine protease inhibitor-thrombin complex, protein C inhibitor-coagulation factor II complex, and SERPINA5-thrombin complex.
Why is the protein C inhibitor-thrombin complex important in coagulation?
It provides a major pathway for thrombin inhibition, preventing excessive clot formation and modulating fibrinolysis.
Can CRISPR be used to study the protein C inhibitor-thrombin complex?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can be used to dissect the roles of SERPINA5 and F2.
What biomarkers are related to the protein C inhibitor-thrombin complex?
The complex itself can serve as a biomarker for thrombin generation and for monitoring anticoagulant therapy.
Conclusion
The protein C inhibitor-thrombin complex (GO:0036028) is a critical regulator of hemostasis, formed by the irreversible binding of SERPINA5 to thrombin. Its study provides insights into coagulation disorders, lung disease, and anticoagulant therapy. Advances in CRISPR gene editing and proteomics continue to unravel its molecular details and disease relevance [1,2,3].
References
- 1. Fujimoto H et al.. 2003. Thrombin-activatable fibrinolysis inhibitor and protein C inhibitor in interstitial lung disease.. Am J Respir Crit Care Med 167(12):1687-94 PMID: 12615624
- 2. Bolt MW et al.. 2020. Evaluation of biomarkers for monitoring thrombogenic potential of FXaI16L.. Blood Coagul Fibrinolysis 31(1):16-28 PMID: 31687988
- 3. Chan AK et al.. 1997. Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass.. Thromb Haemost 77(2):270-7 PMID: 9157580
